Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00124527 · ClinicalTrials.gov registry record · Phase 2

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

A Phase 2 study of Thyroid Cancer, sponsored by Eisai.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
10
Study locations

NCT00124527: Completed Phase 2 study of Thyroid Cancer, sponsored by Eisai.

NCT00124527 is a Phase 2 study of Thyroid Cancer that has completed, run by Eisai. The registered enrollment target is 35 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00124527, a Phase 2 study of Thyroid Cancer, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
10
Study locations

Study Summary

Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.

Conditions Studied

Thyroid Cancer

Interventions

  • DRUG Irofulven + capecitabine

Study Locations (10)

Other

  • - Salta
  • - Lyon
  • - Toulouse
  • - Villejuif
  • - Lima
  • - Moscow
  • - Obninsk
  • - Kiev

Colorado

  • - Aurora

Ohio

  • - Columbus

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2005-03-31
Est. Completion 2006-08-31
Phase Phase 2
Eisai

287 total trials

What the finished NCT00124527 record still lists

NCT00124527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Irofulven + capecitabine is the first listed.

NCT00124527 lists 10 locations in 3 states (Other, Colorado, Ohio).

Frequently Asked Questions

What is clinical trial NCT00124527 about?

NCT00124527 is a clinical study titled "Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer". Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroi...

What is the current status of trial NCT00124527?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-03-31. Estimated completion is 2006-08-31.

What conditions does trial NCT00124527 study?

This clinical trial studies the following conditions: Thyroid Cancer.

What interventions are being tested in trial NCT00124527?

The interventions under investigation include: Irofulven + capecitabine (DRUG).

Who is sponsoring clinical trial NCT00124527?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00124527 being conducted?

This trial has 10 study locations across Colorado, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00124527's enrollment target sits among peer trials

35 30th of 46 higher than 17 of 46 other Thyroid Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT00124527, the US trial registry maintained by the National Library of Medicine. NCT00124527 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.